Primary cutaneous lymphomas have a distinct clinical behavior and prognosis, and therefore require a different therapeutic approach, as compared with their primary nodal equivalents. The European Organization for Research and Treatment of Cancer (EORTC) classification for primary cutaneous lymphomas recognizes a limited number of cutaneous T-cell lymphomas and cutaneous B-cell lymphomas and is ...

The incidence of primary cutaneous lymphomas in the European Union reaches 1/100 000 per year. Primary cutaneous lymphomas originate in the skin and they are restricted to the skin. Secondary cutaneous lymphomas are manifestations of lymphomas of nodal or extranodal origin. Primary cutaneous lymphomas include various lymphoproliferative disorders: 65% are cutaneous T-cell lymphomas (CTCL), 25% ...

The primary cutaneous CD30-positive (CD30+) T-cell lymphoproliferative disorders are a group of largely indolent diseases that manifest as nodules or tumors of the skin. The European Organisation for Research and Treatment of Cancer (EORTC) has developed a modification of the World Health Organization (WHO) lymphoma classification system that specifically categorizes these entities. According t...

REFERENCES 1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127:2375-90. 2. Friedmann D, Wechsler J, Delfau MH, et al. Primary cutaneous pleomorphic small T-cell lymphoma. A review of 11 cases. The French Study Group on Cutaneous Lymphomas. Arch Dermatol 1995;131:1009-15. 3. Gaulard P, Berti E, Wilemze...

Cutaneous T-cell lymphomas most commonly have a CD4(+) memory T-cell phenotype with relatively indolent course, but may in rare cases present with a CD8(+) cytotoxic phenotype exhibiting strikingly more aggressive clinical behavior. We present two cases of the clinically aggressive subtype of primary cutaneous epidermotropic CD8(+) cutaneous T-cell lymphoma and review the current literature, cl...

It is critical to distinguish CD30+ T-cell LPDs from other CD30+ processes involving the skin that include: Systemic lymphomas (eg, systemic ALCL, ATLL, PTCL), Other cutaneous process such as other CD30+ skin lymphomas such as mycosis fungoides (MF), especially transformed MF, cytotoxic T-cell lymphomas, and Benign disorders such as lymphomatoid drug reactions, arthropod bites, viral infections...